Search Results

Intergalactic Therapeutics announced today that it will host a virtual investor event with scientific experts in the fields of ophthalmology, bioengineering, and gene therapy on Tuesday, May 23, 2023 at 10:00 a.m. ET.

Intergalactic Therapeutics today announced positive preclinical data from IG-002, its lead program addressing all forms of ABCA4-related retinopathies.

Intergalactic Therapeutics announced today that it will present two posters highlighting preclinical data for IG-002, Intergalactic’s lead program addressing all forms of ABCA4-related retinopathies, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, being held in Los Angeles, CA, from May 16-20, 2023.

Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced today positive preclinical results from its lead program IG-002 addressing all forms of ABCA4-related retinopathies.

Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced the appointment of Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer.

Intergalactic Therapeutics announced today that Gayathri Ramaswamy, Ph.D., Vice President, Drug Discovery and Disease Biology, will present at the Annual Retinal Cell and Gene Therapy Innovation Summit on April 21, 2023 at the Marriott New Orleans Warehouse Arts District in New Orleans, Louisiana.

Intergalactic Therapeutics, a focal non-viral gene therapy company, has announced members of its Scientific Advisory Board (SAB).

Intergalactic Therapeutics closed on a Series A funding round worth $75 million. The company was launched by Advanced Technology Products Corporation (ATP).